The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study
Abstract
Abstract Rationale Improved therapeutic options are needed for patients with treatment-refractory nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC). Objectives To evaluate the efficacy and safety of daily amikacin liposome inhalation suspension (ALIS) added to standard guideline-based therapy (GBT) in patients with refractory MAC lung disease. Methods Adults with amikacin-susceptible MAC lung disease and MAC-positive sputum cultures despite at least 6 months of stable GBT were randomly assigned (2:1) to receive ALIS with GBT (ALIS + GBT) or GBT alone. Once-daily ALIS was supplied in single-use vials delivering 590 mg amikacin to the nebulizer. The primary endpoint was culture conversion, defined as three consecutive monthly MAC-negative sputum cultures by Month 6. Measurements and Main Results Enrolled patients (ALIS + GBT, n = 224; GBT-alone, n = 112) were a mean 64.7 years old and 69.3% female. Most had underlying bronchiectasis (62.5%), chronic obstructive pulmonary disease (14.3%), or both (11.9%). Culture conversion was achieved by 65 of 224 patients (29.0%) with ALIS + GBT and 10 of 112 (8.9%) with GBT alone (odds ratio, 4.22; 95% confidence interval, 2.08–8.57; P < 0.001). Patients in the ALIS + GBT arm versus GBT alone were more likely to achieve conversion (hazard ratio, 3.90; 95% confidence interval, 2.00–7.60). Respiratory adverse events (primarily dysphonia, cough, and dyspnea) were reported in 87.4% of patients receiving ALIS + GBT and 50.0% receiving GBT alone; serious treatment-emergent adverse events occurred in 20.2% and 17.9% of patients, respectively. Conclusions Addition of ALIS to GBT for treatment-refractory MAC lung disease achieved significantly greater culture conversion by Month 6 than GBT alone, with comparable rates of serious adverse events. Clinical trial registered with www.clinicaltrials.gov (NCT02344004).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Self-citationEpidemiology of Human Pulmonary Infection with Nontuberculous Mycobacteria
Prevots, D. R., & Marras, T. K. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2014.10.002 · Cited by 920
Self-citationHaworth, C. S., Banks, J., Capstick, T., Fisher, A. J., Gorsuch, T., Laurenson, I. F., Leitch, A., Loebinger, M. R., Milburn, H. J., Nightingale, M., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210927 · Cited by 785
Self-citationPrevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare Beneficiaries
Adjemian, J., Olivier, K. N., Seitz, A. E., Holland, S. M., & Prevots, D. R. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201111-2016oc · Cited by 690
Interpreting thresholds for a clinically significant change in health status in asthma and COPD
Jones, P. W. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00063702 · Cited by 585
Nontuberculous Mycobacterial Lung Disease Prevalence at Four Integrated Health Care Delivery Systems
Prevots, D. R., Shaw, P. A., Strickland, D., Jackson, L. A., Raebel, M. A., Blosky, M. A., Montes de Oca, R., Shea, Y. R., Seitz, A. E., Holland, S. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201002-0310oc · Cited by 582
Brown-Elliott, B. A., Nash, K. A., & Wallace, R. J. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05030-11 · Cited by 541
Self-citationRybak, M. J., Abate, B. J., Kang, S. L., Ruffing, M. J., Lerner, S. A., & Drusano, G. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1549 · Cited by 431
Macrolide/Azalide Therapy for Nodular/Bronchiectatic Mycobacterium avium Complex Lung Disease
Wallace, R. J., Brown-Elliott, B. A., McNulty, S., Philley, J. V., Killingley, J., Wilson, R. W., York, D. S., Shepherd, S., & Griffith, D. E. (2014) · Chest · doi:10.1378/chest.13-2538 · Cited by 350
Self-citationAminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases
Peloquin, C. A., Berning, S. E., Nitta, A. T., Simone, P. M., Goble, M., Huitt, G. A., Iseman, M. D., Cook, J. L., & Curran-Everett, D. (2004) · Clinical Infectious Diseases · doi:10.1086/420742 · Cited by 270
van Ingen, J., Aksamit, T., Andrejak, C., Böttger, E. C., Cambau, E., Daley, C. L., Griffith, D. E., Guglielmetti, L., Holland, S. M., Huitt, G. A., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00170-2018 · Cited by 264
Self-citationNontuberculous Pulmonary Mycobacteriosis in Denmark: Incidence and Prognostic Factors
Andréjak, C., Thomsen, V. Ø., Johansen, I. S., Riis, A., Benfield, T. L., Duhaut, P., Sørensen, H. T., Lescure, F.-X., & Thomsen, R. W. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200905-0778oc · Cited by 261
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease
Olivier, K. N., Griffith, D. E., Eagle, G., McGinnis, J. P., Micioni, L., Liu, K., Daley, C. L., Winthrop, K. L., Ruoss, S., Addrizzo-Harris, D. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0700oc · Cited by 254
Self-citationKwak, N., Park, J., Kim, E., Lee, C.-H., Han, S. K., & Yim, J.-J. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix517 · Cited by 222
Self-citationOutcomes of Mycobacterium avium complex lung disease based on clinical phenotype
Koh, W.-J., Moon, S. M., Kim, S.-Y., Woo, M.-A., Kim, S., Jhun, B. W., Park, H. Y., Jeon, K., Huh, H. J., Ki, C.-S., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02503-2016 · Cited by 217
Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010
Marras, T. K., Mendelson, D., Marchand-Austin, A., May, K., & Jamieson, F. B. (2013) · Emerging Infectious Diseases · doi:10.3201/eid1911.130737 · Cited by 210
Self-citationThe Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment
van Ingen, J., Egelund, E. F., Levin, A., Totten, S. E., Boeree, M. J., Mouton, J. W., Aarnoutse, R. E., Heifets, L. B., Peloquin, C. A., & Daley, C. L. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0682oc · Cited by 202
Self-citationA Steady Increase in Nontuberculous Mycobacteriosis Mortality and Estimated Prevalence in Japan
Morimoto, K., Iwai, K., Uchimura, K., Okumura, M., Yoshiyama, T., Yoshimori, K., Ogata, H., Kurashima, A., Gemma, A., & Kudoh, S. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201303-067oc · Cited by 199
Self-citationFactors Related to Response to Intermittent Treatment of Mycobacterium avium Complex Lung Disease
Lam, P. K., Griffith, D. E., Aksamit, T. R., Ruoss, S. J., Garay, S. M., Daley, C. L., & Catanzaro, A. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200509-1531oc · Cited by 187
Self-citationInhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease
Olivier, K. N., Shaw, P. A., Glaser, T. S., Bhattacharyya, D., Fleshner, M., Brewer, C. C., Zalewski, C. K., Folio, L. R., Siegelman, J. R., Shallom, S., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201307-231oc · Cited by 176
Brown-Elliott, B. A., Iakhiaeva, E., Griffith, D. E., Woods, G. L., Stout, J. E., Wolfe, C. R., Turenne, C. Y., & Wallace, R. J. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01612-13 · Cited by 173
Self-citationHigh mortality in patients with Mycobacterium avium complex lung disease: a systematic review
Diel, R., Lipman, M., & Hoefsloot, W. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3113-x · Cited by 165
Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?
Thomas, O. S., & Weber, W. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00415 · Cited by 158
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
Maselli, D. J., Keyt, H., & Restrepo, M. I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051062 · Cited by 109
Rose, S. J., Neville, M. E., Gupta, R., & Bermudez, L. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108703 · Cited by 107
Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients
Modongo, C., Pasipanodya, J. G., Zetola, N. M., Williams, S. M., Sirugo, G., & Gumbo, T. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01050-15 · Cited by 99
Weers, J. G., Metzheiser, B., Taylor, G., Warren, S., Meers, P. R., & Perkins, W. R. (2009) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2008.0693 · Cited by 98
Therapy of refractory nontuberculous mycobacterial lung disease
Griffith, D. E., & Aksamit, T. R. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283511a64 · Cited by 93
Self-citationPulmonary Nontuberculous Mycobacteria–Associated Deaths, Ontario, Canada, 2001–2013
Marras, T. K., Campitelli, M. A., Lu, H., Chung, H., Brode, S. K., Marchand‐Austin, A., Winthrop, K. L., Gershon, A. S., Kwong, J. C., & Jamieson, F. (2017) · Emerging infectious diseases · doi:10.3201/eid2303.161927 · Cited by 87
Self-citationLarsson, L.-O., Polverino, E., Hoefsloot, W., Codecasa, L. R., Diel, R., Jenkins, S. G., & Loebinger, M. R. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1386563 · Cited by 78
Self-citationChou, M. P., Clements, A., & Thomson, R. M. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-279 · Cited by 66
Self-citationGanbat, D., Seehase, S., Richter, E., Vollmer, E., Reiling, N., Fellenberg, K., Gaede, K. I., Kügler, C., & Goldmann, T. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0185-5 · Cited by 66
Yagi, K., Ishii, M., Namkoong, H., Asami, T., Iketani, O., Asakura, T., Suzuki, S., Sugiura, H., Yamada, Y., Nishimura, T., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2665-5 · Cited by 62
Self-citationZweijpfenning, S. M. H., Kops, S. E. P., Magis-Escurra, C., Boeree, M. J., van Ingen, J., & Hoefsloot, W. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.08.031 · Cited by 55
Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease
Jhun, B. W., Yang, B., Moon, S. M., Lee, H. J., Park, H. Y., Jeon, K., Kwon, O. J., Ahn, J., Moon, I. J., Shin, S. J., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00011-18 · Cited by 53
Park, Y., Lee, E. H., Jung, I., Park, G., & Kang, Y. A. (2019) · Respiratory Research · doi:10.1186/s12931-019-1258-9 · Cited by 45
Novosad, S., Henkle, E. M., Schafer, S., Hedberg, K., Ku, J. H., Siegel, S. A. R., Choi, D., Slatore, C. G., & Winthrop, K. L. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201610-800oc · Cited by 44
Self-citationMalinin, V., Neville, M. E., Eagle, G. L., Gupta, R., & Perkins, W. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00700-16 · Cited by 41
Self-citation
Cited by
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00535-2020 · Cited by 924
Self-citationDaley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa241 · Cited by 890
Self-citationNon-tuberculous mycobacteria and the rise of Mycobacterium abscessus
Johansen, M. D., Herrmann, J.-L., & Kremer, L. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0331-1 · Cited by 822
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1125 · Cited by 786
Self-citationShteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32542-3 · Cited by 682
Metadata
- Authors
- Griffith, D. E., Eagle, G., Thomson, R., Aksamit, T. R., Hasegawa, N., Morimoto, K., Addrizzo-Harris, D. J., O’Donnell, A. E., Marras, T. K., Flume, P. A., Loebinger, M. R., Morgan, L., Codecasa, L. R., Hill, A. T., Ruoss, S. J., Yim, J.-J., Ringshausen, F. C., Field, S. K., Philley, J. V., Wallace, R. J., van Ingen, J., Coulter, C., Nezamis, J., & Winthrop, K. L.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-12-15
- Volume
- 198
- Issue
- 12
- Pages
- 1559-1569
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2892323117
- Cited by
- 356
- References
- 38
- FWCI
- 20.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.